Zeitungsständer (Symbolbild).
Mittwoch, 11.10.2017 13:30 von | Aufrufe: 32

Bio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results

Zeitungsständer (Symbolbild). © AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images

PR Newswire

MINNEAPOLIS, Oct. 11, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on October 31, 2017, at 8:00 a.m. CDT to review first quarter 2018 financial results.

Bio-Techne

Access to the discussion may be obtained as follows:

Time:     8:00 a.m. CDT
Date:      October 31, 2017
Dial-in:   1-888-487-0360 or 1-719-325-2412 (for international callers)
Conference ID: 9975102

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call.  To access the recording, U.S. callers should dial 1-844-512-2921 or international callers should dial 1-412-317-6671 and enter the replay access code 9975102. The recording can also be accessed by going to:

The replay will be available from 11:00 a.m. CDT on Tuesday, October 31, 2017 until 11:00 p.m. CDT on Thursday, November 30, 2017.


ARIVA.DE Börsen-Geflüster

Kurse

62,24 $
+0,05%
Bio-Techne Chart

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in-situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.  The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact:

David Clair, Investor Relations


ir@bio-techne.com 


646-277-1266 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-october-31-2017-to-announce-first-quarter-2018-financial-results-300534290.html

SOURCE Bio-Techne Corporation

Werbung

Mehr Nachrichten zur Bio-Techne Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News